Nurix Therapeutics Inc (NRIX)

$14.64 -0.64 (-4.19%)
Market Cap 1.51B
Revenue (ttm) 83.98M
Net Income (ttm) -264.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -314.91%
Debt to Equity Ratio 0.00
Volume 1,633,000
Avg Vol 1,105,190
Day's Range N/A - N/A
Shares Out 103.41M
Stochastic %K 10%
Beta 1.86
Analysts Strong Sell
Price Target $30.18

Company Profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK)...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 660 5320
Fax: 415 525 4200
Address:
1600 Sierra Point Parkway, Brisbane, United States
oaksapollo
oaksapollo Jun. 8 at 5:03 AM
$NRIX @LongTrainRunning this should help https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-global-collaboration-roche-co
1 · Reply
LongTrainRunning
LongTrainRunning Jun. 5 at 6:37 PM
$NRIX Almost at 14 before EHA?? I did not see this coming. Hang tight longs! Remember we were above 22 on ASH 2025 data readout. Just to recap- the data in a week will be more mature than December 2025. We should expect to see improved ORR and DOR for 600mg dose vs mixed 200/600 cohorts. And I think we'll have an edge over BG-16673 for safety because our molecule is much more selective, even if we can't top their ORR, which can lead to fewer discontinuations for our patients. It sucks that we're down $3 over the past week. But if EHA data are good it won't matter what we're at today. This is a golden opportunity to buy today.
0 · Reply
LongTrainRunning
LongTrainRunning May. 31 at 6:56 PM
$NRIX two weeks until EHA. Will this be the last chance to buy under $20? I sure hope so.
2 · Reply
Ravbcentinal
Ravbcentinal May. 27 at 4:04 PM
$NRIX 18 soon
0 · Reply
oaksapollo
oaksapollo May. 15 at 3:16 PM
$NRIX so much potential for each NRIX molecule across indications https://www.nurixtx.com/wp-content/uploads/2026/05/Bexobrutideg-CSU-Talk-at-SID.pdf
0 · Reply
SuperGreenToday
SuperGreenToday May. 12 at 12:22 PM
$NRIX Share Price: $16.30 Contract Selected: Oct 16, 2026 $15 Calls Buy Zone: $3.63 – $4.48 Target Zone: $6.42 – $7.84 Potential Upside: 67% ROI Time to Expiration: 156 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
mikesterz7
mikesterz7 May. 10 at 1:13 PM
$NRIX Nurix Therapeutics, Inc.’s Chief Financial Officer Hans van Houte reported open-market sales of company stock.
0 · Reply
Br331
Br331 May. 10 at 12:48 PM
$NRIX we see 100 soon
0 · Reply
BigCh33z3
BigCh33z3 May. 10 at 12:30 PM
$NRIX
0 · Reply
BigCh33z3
BigCh33z3 May. 10 at 12:30 PM
$NRIX
0 · Reply
Latest News on NRIX
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics

Jun 8, 2026, 1:47 AM EDT - 1 hour ago

Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Jun 8, 2026, 1:00 AM EDT - 2 hours ago

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

Jun 8, 2026, 1:00 AM EDT - 2 hours ago

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

Nurix Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 11:05 AM EDT - 4 days ago

Nurix Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Nurix Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 20, 2026, 1:35 PM EDT - 18 days ago

Nurix Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

May 14, 2026, 4:05 PM EDT - 24 days ago

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

Nurix Therapeutics to Participate in Upcoming Investor Conferences

May 13, 2026, 7:00 AM EDT - 25 days ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

May 12, 2026, 4:05 PM EDT - 26 days ago

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

Apr 22, 2026, 7:00 AM EDT - 6 weeks ago

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

Nurix Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 1:30 PM EDT - 7 weeks ago

Nurix Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Nurix Therapeutics price target lowered to $28 from $29 at Wells Fargo

2026-04-09T10:49:00.000Z - 2 months ago

Nurix Therapeutics price target lowered to $28 from $29 at Wells Fargo

Nurix Therapeutics price target lowered to $34 from $35 at Stifel

2026-04-08T17:40:47.000Z - 2 months ago

Nurix Therapeutics price target lowered to $34 from $35 at Stifel

Nurix Therapeutics reports Q1 EPS (79c), consensus (76c)

2026-04-08T10:09:37.000Z - 2 months ago

Nurix Therapeutics reports Q1 EPS (79c), consensus (76c)

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Apr 8, 2026, 6:00 AM EDT - 2 months ago

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Nurix Therapeutics Earnings release: Q1 2026

Apr 8, 2026, 6:00 AM EDT - 2 months ago

Nurix Therapeutics Earnings release: Q1 2026

Nurix Therapeutics Quarterly report: Q1 2026

Apr 8, 2026, 6:00 AM EDT - 2 months ago

Nurix Therapeutics Quarterly report: Q1 2026

Nurix Therapeutics to Participate in Upcoming Investor Conference

Apr 7, 2026, 7:00 AM EDT - 2 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conference

Nurix Therapeutics Proxy statement: Proxy filing

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Nurix Therapeutics Proxy statement: Proxy filing

Nurix Therapeutics Proxy statement: Proxy filing

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Nurix Therapeutics Proxy statement: Proxy filing

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting

Mar 23, 2026, 4:05 PM EDT - 2 months ago

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting

Nurix Therapeutics Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 12, 2026, 12:00 PM EST - 4 months ago

Nurix Therapeutics Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Nurix Therapeutics price target raised to $35 from $33 at Stifel

2026-01-29T13:36:08.000Z - 4 months ago

Nurix Therapeutics price target raised to $35 from $33 at Stifel

Nurix Therapeutics price target lowered to $29 from $30 at Wells Fargo

2026-01-29T12:45:48.000Z - 4 months ago

Nurix Therapeutics price target lowered to $29 from $30 at Wells Fargo

Nurix Therapeutics price target raised to $35 from $32 at Piper Sandler

2026-01-29T12:11:45.000Z - 4 months ago

Nurix Therapeutics price target raised to $35 from $32 at Piper Sandler

Nurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright

2026-01-29T11:10:51.000Z - 4 months ago

Nurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright

Nurix Therapeutics reports Q4 EPS (82c), consensus (92c)

2026-01-28T21:51:03.000Z - 4 months ago

Nurix Therapeutics reports Q4 EPS (82c), consensus (92c)

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

Jan 28, 2026, 4:01 PM EST - 4 months ago

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

Nurix Therapeutics Annual report: Q4 2025

Jan 28, 2026, 4:00 PM EST - 4 months ago

Nurix Therapeutics Annual report: Q4 2025

Nurix Therapeutics Earnings release: Q4 2025

Jan 28, 2026, 4:00 PM EST - 4 months ago

Nurix Therapeutics Earnings release: Q4 2025

Nurix Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:30 PM EST - 5 months ago

Nurix Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Nurix Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:30 PM EST - 5 months ago

Nurix Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Nurix Therapeutics highlights key objectives, milestones

2026-01-12T12:37:38.000Z - 5 months ago

Nurix Therapeutics highlights key objectives, milestones

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

Jan 12, 2026, 7:00 AM EST - 5 months ago

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

Nurix Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley

2026-01-08T10:05:32.000Z - 5 months ago

Nurix Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley

Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 5 months ago

Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Nurix Therapeutics price target raised to $30 from $24 at Mizuho

2025-12-10T13:15:53.000Z - 6 months ago

Nurix Therapeutics price target raised to $30 from $24 at Mizuho

ONC

Nurix Therapeutics price target raised to $31 from $28 at H.C. Wainwright

2025-12-10T11:16:35.000Z - 6 months ago

Nurix Therapeutics price target raised to $31 from $28 at H.C. Wainwright

Nurix Therapeutics price target raised to $30 from $27 at BTIG

2025-12-09T12:15:29.000Z - 6 months ago

Nurix Therapeutics price target raised to $30 from $27 at BTIG

Nurix Therapeutics Transcript: Study Update

Dec 8, 2025, 8:15 PM EST - 6 months ago

Nurix Therapeutics Transcript: Study Update

Nurix Therapeutics Press release: Study Update

Dec 8, 2025, 8:15 PM EST - 6 months ago

Nurix Therapeutics Press release: Study Update

Nurix Therapeutics presents data from Phase 1 trial of bexobrutideg

2025-12-08T13:20:27.000Z - 6 months ago

Nurix Therapeutics presents data from Phase 1 trial of bexobrutideg

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 8, 2025, 8:00 AM EST - 6 months ago

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Nurix presents new clinical data from Phase 1a/1b NX-5948-301 study

2025-12-07T18:10:10.000Z - 6 months ago

Nurix presents new clinical data from Phase 1a/1b NX-5948-301 study

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Dec 6, 2025, 9:30 AM EST - 6 months ago

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Nurix Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 12:30 PM EST - 6 months ago

Nurix Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 1, 2025, 7:00 AM EST - 6 months ago

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 7:00 AM EST - 6 months ago

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nurix Therapeutics assumed with a Buy at Truist

2025-11-24T13:55:32.000Z - 6 months ago

Nurix Therapeutics assumed with a Buy at Truist

Nurix Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 6:00 AM EST - 7 months ago

Nurix Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nurix Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 9:20 AM EST - 7 months ago

Nurix Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

Nov 10, 2025, 7:00 AM EST - 7 months ago

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

Nov 7, 2025, 9:00 AM EST - 7 months ago

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Nov 3, 2025, 9:00 AM EST - 7 months ago

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

Oct 27, 2025, 7:00 AM EDT - 7 months ago

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

Nurix Therapeutics Transcript: Study Update

Oct 22, 2025, 8:00 AM EDT - 8 months ago

Nurix Therapeutics Transcript: Study Update

Nurix Therapeutics Press release: Study Update

Oct 22, 2025, 8:00 AM EDT - 8 months ago

Nurix Therapeutics Press release: Study Update

Nurix Therapeutics Slides: Study Update

Oct 22, 2025, 8:00 AM EDT - 8 months ago

Nurix Therapeutics Slides: Study Update

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

Oct 22, 2025, 7:20 AM EDT - 8 months ago

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

Oct 22, 2025, 6:00 AM EDT - 8 months ago

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

Oct 18, 2025, 3:00 AM EDT - 8 months ago

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Oct 9, 2025, 4:01 PM EDT - 8 months ago

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nurix Therapeutics Earnings release: Q3 2025

Oct 9, 2025, 4:00 PM EDT - 8 months ago

Nurix Therapeutics Earnings release: Q3 2025

Nurix Therapeutics Quarterly report: Q3 2025

Oct 9, 2025, 4:00 PM EDT - 8 months ago

Nurix Therapeutics Quarterly report: Q3 2025

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Sep 17, 2025, 7:00 AM EDT - 9 months ago

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Nurix Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 16, 2025, 11:00 AM EDT - 9 months ago

Nurix Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Nurix Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 7:00 AM EDT - 9 months ago

Nurix Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Nurix Therapeutics Transcript: Baird Global Healthcare Conference 2025

Sep 9, 2025, 10:50 AM EDT - 9 months ago

Nurix Therapeutics Transcript: Baird Global Healthcare Conference 2025

Nurix Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 1:30 PM EDT - 9 months ago

Nurix Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Nurix Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 1:30 PM EDT - 9 months ago

Nurix Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Nurix Therapeutics Slides: FY 2025

Sep 3, 2025, 1:30 PM EDT - 9 months ago

Nurix Therapeutics Slides: FY 2025

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 9, 2025, 4:01 PM EDT - 11 months ago

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Nurix Therapeutics Earnings release: Q2 2025

Jul 9, 2025, 7:00 AM EDT - 11 months ago

Nurix Therapeutics Earnings release: Q2 2025

Nurix Therapeutics Quarterly report: Q2 2025

Jul 9, 2025, 7:00 AM EDT - 11 months ago

Nurix Therapeutics Quarterly report: Q2 2025

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

Jul 7, 2025, 7:00 AM EDT - 11 months ago

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 13, 2025, 4:01 PM EDT - 1 year ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics Transcript: Study Update

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Nurix Therapeutics Transcript: Study Update

Nurix Therapeutics Press release: Study Update

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Nurix Therapeutics Press release: Study Update

Nurix Therapeutics Slides: Study Update

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Nurix Therapeutics Slides: Study Update

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Jun 12, 2025, 7:00 AM EDT - 1 year ago

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Jun 6, 2025, 7:00 AM EDT - 1 year ago

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Nurix Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 3:45 PM EDT - 1 year ago

Nurix Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

Jun 2, 2025, 7:00 AM EDT - 1 year ago

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 7:00 AM EDT - 1 year ago

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

Nurix Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 21, 2025, 2:05 PM EDT - 1 year ago

Nurix Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 1 year ago

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

May 14, 2025, 9:30 AM EDT - 1 year ago

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Apr 28, 2025, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Apr 25, 2025, 1:00 PM EDT - 1 year ago

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Apr 17, 2025, 7:00 AM EDT - 1 year ago

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 8, 2025, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Nurix Therapeutics Quarterly report: Q1 2025

Apr 8, 2025, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Quarterly report: Q1 2025

Nurix Therapeutics Earnings release: Q1 2025

Apr 8, 2025, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Earnings release: Q1 2025

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Apr 2, 2025, 7:00 AM EDT - 1 year ago

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Nurix Therapeutics Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Nurix Therapeutics Proxy statement: Proxy Filing

Nurix Therapeutics Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Nurix Therapeutics Proxy statement: Proxy Filing

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch.

Mar 13, 2025, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch.

Nurix Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 12, 2025, 10:00 AM EDT - 1 year ago

Nurix Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Nurix Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 11, 2025, 12:40 PM EST - 1 year ago

Nurix Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 1 year ago

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Jan 28, 2025, 4:00 PM EST - 1 year ago

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Nurix Therapeutics Earnings release: Q4 2024

Jan 28, 2025, 4:00 PM EST - 1 year ago

Nurix Therapeutics Earnings release: Q4 2024

Nurix Therapeutics Annual report: Q4 2024

Jan 28, 2025, 4:00 PM EST - 1 year ago

Nurix Therapeutics Annual report: Q4 2024

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

Jan 22, 2025, 7:00 AM EST - 1 year ago

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

Nurix Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 6:00 PM EST - 1 year ago

Nurix Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 7:00 AM EST - 1 year ago

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia

Dec 19, 2024, 7:00 AM EST - 1 year ago

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia

Nurix Therapeutics Transcript: The 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024

Dec 9, 2024, 11:15 PM EST - 1 year ago

Nurix Therapeutics Transcript: The 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024

Nurix Therapeutics Slides: FY 2024

Dec 9, 2024, 11:15 PM EST - 1 year ago

Nurix Therapeutics Slides: FY 2024

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

Dec 9, 2024, 6:00 PM EST - 1 year ago

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

Nurix Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 2:30 PM EST - 1 year ago

Nurix Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

Dec 2, 2024, 7:00 AM EST - 1 year ago

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

oaksapollo
oaksapollo Jun. 8 at 5:03 AM
$NRIX @LongTrainRunning this should help https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-global-collaboration-roche-co
1 · Reply
LongTrainRunning
LongTrainRunning Jun. 5 at 6:37 PM
$NRIX Almost at 14 before EHA?? I did not see this coming. Hang tight longs! Remember we were above 22 on ASH 2025 data readout. Just to recap- the data in a week will be more mature than December 2025. We should expect to see improved ORR and DOR for 600mg dose vs mixed 200/600 cohorts. And I think we'll have an edge over BG-16673 for safety because our molecule is much more selective, even if we can't top their ORR, which can lead to fewer discontinuations for our patients. It sucks that we're down $3 over the past week. But if EHA data are good it won't matter what we're at today. This is a golden opportunity to buy today.
0 · Reply
LongTrainRunning
LongTrainRunning May. 31 at 6:56 PM
$NRIX two weeks until EHA. Will this be the last chance to buy under $20? I sure hope so.
2 · Reply
Ravbcentinal
Ravbcentinal May. 27 at 4:04 PM
$NRIX 18 soon
0 · Reply
oaksapollo
oaksapollo May. 15 at 3:16 PM
$NRIX so much potential for each NRIX molecule across indications https://www.nurixtx.com/wp-content/uploads/2026/05/Bexobrutideg-CSU-Talk-at-SID.pdf
0 · Reply
SuperGreenToday
SuperGreenToday May. 12 at 12:22 PM
$NRIX Share Price: $16.30 Contract Selected: Oct 16, 2026 $15 Calls Buy Zone: $3.63 – $4.48 Target Zone: $6.42 – $7.84 Potential Upside: 67% ROI Time to Expiration: 156 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
mikesterz7
mikesterz7 May. 10 at 1:13 PM
$NRIX Nurix Therapeutics, Inc.’s Chief Financial Officer Hans van Houte reported open-market sales of company stock.
0 · Reply
Br331
Br331 May. 10 at 12:48 PM
$NRIX we see 100 soon
0 · Reply
BigCh33z3
BigCh33z3 May. 10 at 12:30 PM
$NRIX
0 · Reply
BigCh33z3
BigCh33z3 May. 10 at 12:30 PM
$NRIX
0 · Reply
BigCh33z3
BigCh33z3 May. 10 at 12:30 PM
$NRIX
0 · Reply
BigCh33z3
BigCh33z3 May. 10 at 12:30 PM
$NRIX
0 · Reply
BigCh33z3
BigCh33z3 May. 10 at 12:30 PM
$NRIX
0 · Reply
BigCh33z3
BigCh33z3 May. 10 at 12:30 PM
$NRIX
0 · Reply
StreetwiseReports
StreetwiseReports Apr. 28 at 4:06 PM
California Biopharma Co. Uncovers Massive Oncology Breakthrough https://ow.ly/eKKR50YRb28 Nurix Therapeutics Inc. ( $NRIX ) new cancer pipeline data highlights powerful targeted protein degradation advances, with analysts projecting 92% upside potential.
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 28 at 3:22 PM
$NRIX Current Stock Price: $17.34 Contracts to trade: $17.0 NRIX May 15 2026 Call Entry: $0.05 Exit: $0.09 ROI: 77% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
StreetwiseReports
StreetwiseReports Apr. 27 at 3:54 PM
Brisbane Biotech Showcases Degrader Pipeline Advantages at AACR https://ow.ly/NBSB50YQFeq Nurix Therapeutics ( $NRIX ) recently showcased AACR presentations that highlighted the mechanistic superiority of the company's protein degrader platform and preclinical data across key pipeline assets, NX-1607, NRX-4972.
0 · Reply
oaksapollo
oaksapollo Apr. 24 at 7:11 PM
$NRIX new deck on my FAVORITE Nurix molecule: https://www.nurixtx.com/wp-content/uploads/2026/04/AACR-2026-%E2%80%94-CBL-B-Glue-Inhibitors-Presentation.pdf I think 1607+anti-PD1 will be one of the most effective cancer treatments (across tumor types) that we've ever seen.
0 · Reply
oaksapollo
oaksapollo Apr. 23 at 4:57 PM
$NRIX In this biotech environment, I don't understand how no one has bought Nurix. I'm not saying I want it to happen, but if Lilly is willing to pay up to $7B for Kelonia, how in the hell is no one chasing Nurix for their degrader platform (and robust pipeline) which is currently valued at <$2B (a steal!) IMO degraders are the next revolution in medicine. We started with small molecules, then biologics (primarily MAbs), cell therapy like CAR T, and now degraders are next. If Nurix is still an independent company at YE, I will be very surprised
2 · Reply
oaksapollo
oaksapollo Apr. 22 at 4:28 PM
$NRIX Some new data posted https://www.nurixtx.com/resource-library/
0 · Reply
LongTrainRunning
LongTrainRunning Apr. 22 at 1:30 PM
$NRIX EHA is just 7 weeks away. Let's hear your price predictions. I'm hoping we'll see $20 just before EHA and then $25 when we get new data.
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 7:41 AM
$PRLD next catalyst will be DAC partnership. Even though pipeline is early each asset has best-in-class potential in large TAMs RA funding (following Incyte partnership) further validates the potential. Recent expansion of $CCCC partnership with Roche also validates DAC interest. Not many public small/mid-cap DAC players $PRLD $CCCC $NRIX $GYRE (other?)
1 · Reply